1. Bemfola® fixed dose pens potentially reduce drug wastage and associated costs of infertility treatment
- Author
-
Paul Mitchell, Julian M. Jenkins, Helen Kendrew, Nikki Turner, Graham Foxon, and Anne McConnell
- Subjects
Drug ,Infertility ,Gynecology ,medicine.medical_specialty ,Potential impact ,030219 obstetrics & reproductive medicine ,business.industry ,media_common.quotation_subject ,Ultrasound scan ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Fixed dose ,Vial ,03 medical and health sciences ,0302 clinical medicine ,Reproductive Medicine ,Dose adjustment ,Internal medicine ,medicine ,030212 general & internal medicine ,Medical prescription ,business ,media_common - Abstract
Bemfola® is a recombinant follicle-stimulating hormone (FSH) used during infertility treatment. One main differentiator between FSH products is their delivery device; consisting of multi-dose pens (Gonal-f®), vials or multi-dose preparations (Menopur®), or adjustable daily disposable dose pens (Bemfola®). To determine the potential impact of delivery device on drug wastage during infertility treatment this study retrospectively analysed Gonal-f® and Menopur® prescription and usage data from five UK clinics. Incurred drug wastage was then compared to potential Bemfola® drug wastage. Data collected included: (i) number of treatment cycles; (ii) daily FSH dose; (iii) length of treatment; (iv) dose adjustment following ultrasound scan; (v) FSH formulation(s) prescribed and (vi) agonist/antagonist protocol used. Treatment with Gonal-f® (4078 cycles) and Menopur® (646 cycles) resulted in an average drug wastage of 160 and 294 IU per treatment cycle. Use of Bemfola® instead of Gonal-f® and Menopur® may r...
- Published
- 2017
- Full Text
- View/download PDF